Lehigh Valley Health Network

Department of Medicine

Primary Pulmonary Carcinoid Tumors: A Single Institution Retrospective Review: Topic: Medical Oncology

Samuel Adediran MD Lehigh Valley Health Network, Samuel.Adediran@lvhn.org

Eliot L. Friedman MD Lehigh Valley Health Network, Eliot_L.Friedman@lvhn.org

Ranjit R. Nair MD Lehigh Valley Health Network, Ranjit_R.Nair@lvhn.org

Follow this and additional works at: https://scholarlyworks.lvhn.org/medicine

Part of the Hematology Commons, Medical Sciences Commons, and the Oncology Commons Let us know how access to this document benefits you

Published In/Presented At

Adediran, S. Friedman, E. L., Nair, R. (2017, September 14-16). PS02.27 *Primary Pulmonary Carcinoid Tumors: A Single Institution Retrospective Review*. Poster Presented at: The 2017 Chicago Multidisciplinary Symposium in Thoracic Oncology, Chicago, Illiniois.

This Poster is brought to you for free and open access by LVHN Scholarly Works. It has been accepted for inclusion in LVHN Scholarly Works by an authorized administrator. For more information, please contact LibraryServices@lvhn.org.

Primary Pulmonary Carcinoid Tumors: A Single Institution Retrospective Review

BACKGROUND

Pulmonary carcinoid tumors account for 1–2% of all invasive lung malignancies. They generally occur between the fourth and the sixth decade of life. Most pulmonary carcinoid tumors are well differentiated, have < 2 mitoses/10 HPF and < 3% Ki67 index (typical carcinoid). A small percentage are aggressive, have 2-20 mitoses/10 HPF and 3-20% Ki67 index (atypical carcinoid). Because of their rarity, there are very few large studies on pulmonary carcinoid and most of them are retrospective in nature. We present a retrospective analysis of the clinico-pathologic features of patients diagnosed with pulmonary carcinoids tumor at our institution over a ten year period.

METHODS

After approval by the institutional review board, we identify all patients with pulmonary carcinoid tumors diagnosed or treated at the Lehigh Valley Hospital between 2005 and 2015. We performed a retrospective review of the records of all biopsyconfirmed patients with pulmonary carcinoid tumors. Collected data included clinical presentation, demographics, pathology, treatment modalities, pattern of metastases and recurrence. All analyses were conducted using SAS version 9.3. Kaplan-Meier method was used for overall survival calculation.

Samuel Adediran MD, Ranjit Nair, MD and Eliot Friedman, MD Division of Hematology and Medical Oncology, Lehigh Valley Health Network, Allentown, Pennsylvania

Patient Characteristics						
Characteristics						
Gender						
Male	69%					
Female	31%					
Median age	63.5 years (IQR 52, 73)					
Tumor Types						
Typical carcinoid	90%					
Atypical carcinoid	10%					
Tobacco use						
Smoke(d)	44%					
Never smoked	56%					

Stage of Cancer at Time of Diagnosis **Based on TNM Staging Criteria**

Stage	Frequency (%)	
	75	
II	5	
Ш	4	
IV	6	
Multifocal disease	10	

Presenting Symptoms				
Symptoms	Frequency (%)			
Cough	22			
Dyspnea	17			
Chest pain	11			
Pneumonia	9			
Hemoptysis	6			
Incidental finding	56			

Treatment Modalities

0% of Patients Underwent Definitive Invasive Intervention

Intervention/Extent of Resection	Frequency (%)	
Lobectomy	62	
Wedge resection	20	
Segmental resection	4	
Pneumonectomy	4	
Endobronchial ablation	2	

This study though retrospective in nature nevertheless add to the clinico-pathologic features known of pulmonary carcinoid tumor. It is more common in women and occur mostly in the 5th to 6th decades of life. While most tumors are incidental findings on imaging, the common presenting symptoms are cough, dyspnea, chest pain, pneumonia and hemoptysis. Surgery is the mainstay of treatment. Chemotherapy and radiation therapy are rarely used except in the metastatic setting. Keeping with the indolent nature of the disease, most patients that died during the study period died of causes other than pulmonary carcinoid, and disease recurrence was rare.

References:

- 1. Caplin ME, Baudin E, Ferolla P, Filosso P, et. al. ENETS consensus conference participants Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Ann of Oncology 2015 Aug;26(8):1604-20.5. Jayaraman V, Hammerle C, Lo SK, et al. Clinical Application and Outcomes of Over the Scope Clip Device: Initial US Experience in Humans. *Diagn Ther Endosc* 2013;2013:381873.
- 2. Fink G, Krelbaum T, Yellin A, Bendayan D, Saute M, Glazer M, Kramer MR. Pulmonary carcinoid: presentation, diagnosis, and outcome in 142 cases in Israel and review of 640 cases from the literature. Chest. 2001 Jun;119(6):1647-51
- 3. Wolin EM Challenges in the Diagnosis and Management of Well-Differentiated Neuroendocrine Tumors of the Lung (Typical and Atypical Carcinoid): Current Status and Future Considerations. Oncologist. 2015 Oct;20(10):1123-31.
- 4. Kaifi JT, Kayser G, Ruf J, Passlick B. The Diagnosis and Treatment of Bronchopulmonary Carcinoid. Dtsch Arztebl Int. 2015 Jul 6;112(27-28):479-85.
- 5. Herde RF, Kokeny KE, Reddy CB, Akerley WL, Hu N, Boltax JP, Hitchcock YJ. Primary Pulmonary Carcinoid Tumor: A Long-term Single Institution Experience. Am J Clin Oncol. 2015 Aug 11.

RESULTS


Treatments of the 6 Patients with Stage IV Disease							
Patients	Type of Carcinoid	Site of Metastases	Surgical Intervention	Chemotherapy	Outcome		
Patient A	Typical	Bilateral lungs	Endobronchial ablation	None	Indolent disease, lived >5 yea from diagnosis		
Patient B	Typical	Bilateral lungs	None	None	Indolent disease, Aliave >1 y after diagnosis		
Patient C	Atypical	Bone	None	6 cycles of cisplatin and etoposide followed by 6300 cGy RT to residual tumor in the Mediastinum	Alive 4 years after treatment		
Patient D	Typical	Bone	None	Unknown agents followed by palliation RT to the bone	Died <2 years after diagnosis		
Patient E	Atypical	Liver, Lung, Bone, Brain	None	1st line: cisplatin+etoposide. PCI 2nd: carboplatin+paclitaxel, 3rd: 1 cycle of gemcitabine GK	Died 15 months after diagnos		
Patient F	Typical	Lungs	Wedge resection of main tumor	None	Alive 3 years after diagnosis		


Two other patients received chemotherapy: one was misdiagnosed small cell lung carcinoma and the other was s tage IIIA pulmonary carcinoid tumor.


CONCLUSIONS

Survival Results

ients died during the study period: 9 of them of causes other than pulmonary carcinoid. The two patients that died of pulmonary carcinoid both had atypical histology.







© 2017 Lehigh Valley Health Network

610-402-CARE LVHN.org

